FindTrial
Sign In

Visugromab RDE (recommended dose for expansion)

BIOLOGICAL2 trials

Sponsors

CatalYm GmbH

Conditions

Adult Solid TumorChild-Pugh A Hepatocellular CarcinomaFailure of First-Line Treatment That Included an Approved Anti PD-(L)1 CompoundMetastatic Non-Squamous Non-Small Cell Lung CancerUnresectable or Metastatic Hepatocellular Carcinoma

Phase 2

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure
RecruitingNCT07219459
CatalYm GmbHChild-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound, Unresectable or Metastatic Hepatocellular Carcinoma
Start: 2026-03-19End: 2031-09-01Target: 104Updated: 2026-07-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
RecruitingNCT07246863
CatalYm GmbHAdult Solid Tumor, Metastatic Non-Squamous Non-Small Cell Lung Cancer
Start: 2025-10-07End: 2031-10-01Target: 131Updated: 2026-08-19